scholarly journals The Use of Bisphosphonate-Hydroxyapatite Composite in Bone Augmentation

2020 ◽  
Vol 71 (6) ◽  
pp. 22-30
Author(s):  
Sorin Cristian Doca ◽  
Gabriela Vlase ◽  
Titus Vlase ◽  
Atena Galuscan ◽  
Octavia Balean ◽  
...  
Keyword(s):  
Side Effects ◽  
Bone Augmentation ◽  
Chemical Methods ◽  
Physico Chemical ◽  
Hydroxyapatite Composite ◽  
Gastrointestinal Side Effects ◽  
Biomimetic Hydroxyapatite ◽  
Total Elimination ◽  
Injectable Form ◽  
Osteoclast Apoptosis

A good bone augmentation and regeneration depends essentially on the use of a high biomimetic hydroxyapatite, respectively of an osteoclast apoptosis promoting compound. The last one, used in oral or injectable form, leads to different gastrointestinal side effects. We suggested and studied, at non-clinical level, a composite of sodium alendronate linked on a biogene hydroxyapatite. The composite was obtained by putting an aqueous solution of alendronate into a suspension of hydroxyapatite in acetone. By physico-chemical methods the binding of alendronate (ALE) on hydroxyapatite was proved, the content of ALE in the composite being 22%. The patients can benefit from this composite due to a total elimination of gastrointestinal side effects as a consequence of limiting the bioactivity only locally.

Sulfinpyrazone or Acetylsalicylic Acid to Prevent Postoperative Thrombus Formation in Arteriovenous Fistulas of Haemodialysis Patients

1979 ◽  
Author(s):  
F Albert ◽  
U Schmidt
Keyword(s):  
Side Effects ◽  
Acetylsalicylic Acid ◽  
Thrombus Formation ◽  
Significant Inhibition ◽  
High Rate ◽  
Controlled Clinical Trial ◽  
Arteriovenous Fistulas ◽  
Arteriovenous Shunts ◽  
Gastrointestinal Side Effects ◽  
Antithrombotic Efficacy

The effect of sulfinpyrazone (200 mg three times a day) and acetylsalicylic acid (500 mg three times a day) on the incidence of thrombosis of arteriovenous shunts was investigated in a controlled clinical trial. In 36 patients with chronic renal failure scheduled to begin haemodialysis the same operating team constructed a subcutaneous fistula in the distal forearm. During the first six weeks after the operation the antithrombotic efficacy proved to be good for both substances. No differences of thrombotic events between the two treatment groups were statistically significant. But in contrast to acetylsalicylic acid sulfinpyrazone made no significant inhibition of platelet - aggregation; sulfinpyrazone probably will prevent the clot formation by prolonging the shortened platelet survival in uraemic patients. In a high rate of patients given acetylsalicylic acid (10 out of 17) there were local bleeding and gastrointestinal side effects. In consequence we should prefer sulfinpyrazone, because in the sulfinpyrazone group side effects were minimal and in none patient withdrawal from the study was necessitated.

scholarly journals Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota

2021 ◽  
Vol 12 (2) ◽  
pp. 491-502
Author(s):  
Sarah R. Bloor ◽  
Rudolph Schutte ◽  
Anthony R. Hobson
Keyword(s):  
Side Effects ◽  
Gut Microbiota ◽  
Iron Supplementation ◽  
Methanogenic Archaea ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Intestinal Lumen ◽  
Gastrointestinal Side Effects ◽  
Potential Link ◽  
The Impact

Iron deficiency anaemia (IDA) is a worldwide healthcare problem affecting approximately 25% of the global population. The most common IDA treatment is oral iron supplementation, which has been associated with gastrointestinal (GI) side effects such as constipation and bloating. These can result in treatment non-adherence and the persistence of IDA. Intravenous iron does not cause GI side effects, which may be due to the lack of exposure to the intestinal lumen. Luminal iron can cause changes to the gut microbiota, aiding the promotion of pathogenic species and decreasing beneficial protective species. Iron is vital for methanogenic archaea, which rely on iron for growth and metabolism. Increased intestinal methane has been associated with slowing of intestinal transit, constipation, and bloating. Here we explore the literature to understand a potential link between iron and methanogenesis as a novel way to understand the mechanism of oral iron supplementation induced GI side effects.

scholarly journals Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jane L. Tarry-Adkins ◽  
Susan E. Ozanne ◽  
Catherine E. Aiken
Keyword(s):  
Side Effects ◽  
Pregnancy Outcomes ◽  
Gestational Hypertension ◽  
Risk Of Bias ◽  
Maternal Outcomes ◽  
Metformin Treatment ◽  
Eligibility Criteria ◽  
Treatment Groups ◽  
Gastrointestinal Side Effects ◽  
The Impact

AbstractWe systematically assessed the impact of metformin treatment on maternal pregnancy outcomes. PubMed, Ovid Embase, Medline, Web of Science, ClinicalTrials.gov and Cochrane databases were systematically searched (inception-1st February 2021). Randomised controlled trials reporting pregnancy outcomes in women randomised to metformin versus any other treatment for any indication were included. Outcomes included gestational weight gain (GWG), pre-eclampsia, gestational hypertension, preterm birth, gestational age at delivery, caesarean section, gestational diabetes, glycaemic control, and gastrointestinal side-effects. Two independent reviewers conducted screening, with a third available to evaluate disagreements. Risk-of-bias and GRADE assessments were conducted using Cochrane Risk-of-Bias and GRADE-pro software. Thirty-five studies (n = 8033 pregnancies) met eligibility criteria. GWG was lower in pregnancies randomised to metformin versus other treatments (1.57 kg ± 0.60 kg; I2 = 86%, p < 0.0001), as was likelihood of pre-eclampsia (OR 0.69, 95% CI 0.50–0.95; I2 = 55%, p = 0.02). The risk of gastrointestinal side-effects was greater in metformin-exposed versus other treatment groups (OR 2.43, 95% CI 1.53–3.84; I2 = 76%, p = 0.0002). The risk of other maternal outcomes assessed was not significantly different between metformin-exposed versus other treatment groups. Metformin for any indication during pregnancy is associated with lower GWG and a modest reduced risk of pre-eclampsia, but increased gastrointestinal side-effects compared to other treatments.

scholarly journals Contribution of Nanomaterials to the Development of Electrochemical Aptasensors for the Detection of Antimicrobial Residues in Food Products

Chemosensors ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 69
Author(s):  
Valérie Gaudin
Keyword(s):  
Signal Amplification ◽  
Electrochemical Sensors ◽  
Low Cost ◽  
Food Products ◽  
Animal Origin ◽  
Screening Methods ◽  
Chemical Methods ◽  
Portable Instrumentation ◽  
Physico Chemical ◽  
Antimicrobial Residues

The detection of antimicrobial residues in food products of animal origin is of utmost importance. Indeed antimicrobial residues could be present in animal derived food products because of animal treatments for curative purposes or from illegal use. The usual screening methods to detect antimicrobial residues in food are microbiological, immunological or physico-chemical methods. The development of biosensors to propose sensitive, cheap and quick alternatives to classical methods is constantly increasing. Aptasensors are one of the major trends proposed in the literature, in parallel with the development of immunosensors based on antibodies. The characteristics of electrochemical sensors (i.e., low cost, miniaturization, and portable instrumentation) make them very good candidates to develop screening methods for antimicrobial residues in food products. This review will focus on the recent advances in the development of electrochemical aptasensors for the detection of antimicrobial residues in food products. The contribution of nanomaterials to improve the performance characteristics of electrochemical aptasensors (e.g., Sensitivity, easiness, stability) in the last ten years, as well as signal amplification techniques will be highlighted.

Risks of Cardiovascular Disease and Beyond in Prescription of Nonsteroidal Anti-Inflammatory Drugs

2019 ◽  
Vol 25 (1) ◽  
pp. 3-6 ◽  
Author(s):  
Manas A. Rane ◽  
Alexander Gitin ◽  
Benjamin Fiedler ◽  
Lawrence Fiedler ◽  
Charles H. Hennekens
Keyword(s):  
Cardiovascular Disease ◽  
Side Effects ◽  
Health Care Providers ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Care Providers ◽  
Relieve Pain ◽  
Gastrointestinal Side Effects ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin, naproxen, diclofenac, and ibuprofen, as well as selective cyclooxygenase 2 inhibitors such as celecoxib. Their use is common, as well as their side effects which cause 100 000 hospitalizations and 17 000 deaths annually. Recently, the US Food and Drug Administration strengthened its warning about the risks of cardiovascular disease (CVD) attributed to nonaspirin NSAIDs. Methods: When the sample size is large, randomization provides control of confounding not possible to achieve with any observational study. Further, observational studies and, especially, claims data have inherent confounding by indication larger than the small to moderate effects being sought. Results: While trials are necessary, they must be of sufficient size and duration and achieve high compliance and follow-up. Until then, clinicians should remain uncertain about benefits and risks of these drugs. Conclusions: Since the totality of evidence remains incomplete, health-care providers should consider all these aforementioned benefits and risks, both CVD and beyond, in deciding whether and, if so, which, NSAID to prescribe. The factors in the decision of whether and, if so, which NSAID to prescribe for relief of pain from inflammatory arthritis should not be limited to risks of CVD or gastrointestinal side effects but should also include potential benefits including improvements in overall quality of life resulting from decreases in pain or impairment from musculoskeletal pain syndromes. The judicious individual clinical decision-making about the prescription of NSAIDs to relieve pain based on all these considerations has the potential to do much more good than harm.

scholarly journals The principle of formaldehyde, alcohol, and acetone titrations. With a discussion of the proof and implication of the zwitterion conception

1934 ◽  
Vol 115 (792) ◽  
pp. 121-141 ◽  
Keyword(s):  
Amino Acids ◽  
Carboxyl Groups ◽  
Recent Discussion ◽  
Amino Groups ◽  
Chemical Methods ◽  
Titration Method ◽  
Physico Chemical ◽  
Empirical Argument ◽  
Chemical Evidence

Consideration of the implications of the zwitterion hypothesis of Bjerrum (1923) makes it desirable to state afresh the principles underlying the methods commonly employed in the titration of amino-acids. Deductions of considerable theoretical importance, cf., e. g ., Calvery (1933) are still being made on the supposition that the alkalimetric formaldehyde titration method of Sørensen (1907) and the corresponding alcohol method of Foreman (1920) and of Willstätter and Waldschmidt-Leitz (1921) estimate the carboxyl groups of amino-acids whilst the acidimetric acetone titration of Linderstrøm-Lang (1928) estimates the amino-groups. Yet the zwitterion hypothesis indicates that this assumption is the reverse of the truth. Discussion is greatly facilitated by collective consideration of recent physico-chemical evidence clarifying the principles upon which these common bio-chemical methods rest. In a recent discussion of two of the titrimetric methods (Van Slyke and Kirk, 1933) the existence of this evidence is ignored, so that it becomes necessary to systematize and elaborate the empirical argument of these authors in the light of the relevant investigations of Grünhut (1919), Cray and Westrip (1925), Michaelis and Mizutani (1925), Birch and Harris (1930, b ), and Levy (1933). At the same time new and useful developments are indicated.

Sign in / Sign up

Export Citation Format

Share Document